Learn how a food bolus impaction event can help identify a patient with EoE and the importance of multiple disease domains in assessing EoE.
Learn how to recognize adaptive eating behaviors in patients with EoE and why it is important for assessment and management.

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.

The infographic provides information about the clinical characteristics used to classify moderate COPD exacerbations and the impact of these events on lung function, future risk, and mortality.
Join Professors Matthias Augustin and Sarina Elmariah for an engaging ADVENT symposium as they explore the pivotal role of type 2 inflammation in prurigo nodularis and chronic itch.
Join allergist Dr. Nicole Chase and dermatologist Dr. Jason Hawkes as they dispel common myths in the management of chronic spontaneous urticaria (CSU). They offer practical, empathetic strategies to move beyond unnecessary diagnostics and delays, focusing instead on urgent treatment escalation and effective management to reduce the profound burden of uncontrolled CSU on patients.
Prof. Greuter presents clinical data for approved treatments for adult EoE.

Dr Henrik Watz discusses the two main COPD phenotypes: emphysema-predominant and bronchitis-predominant, detectable via clinical assessment and CT imaging.

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
Profs. Greuter, Savarino, and Giordano discuss multidimensional EoE assessment, tailoring long-term care to patient needs, and recent clinical data.

In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses about indirect comparison of biologics for CRSwNP, focusing on clinical outcomes like symptom relief and safety and also highlights dupilumab, omalizumab, and mepolizumab as effective and well-tolerated options.
Join Dr. Miguel Lanz as he explains the clinical utility of FeNO as a biomarker of severe asthma.